Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Palliser is only holding their stake like this to avoid tax, its standard among many funds. Some bank/nominee is holding the real shares and is issuing certificates or derivatives to them, but it just get reverted when the Palliser wants to exit the position.
I think it was a bit arrogant by the management not to spend more time answering question shareholder have pre-submitted.
David first question on the call was if they are going to raise capital. His answer was all but clear.
Its Larry discretion to choose to convert or not, so I cant see why he wouldnt convert all of it eventually. If Barryroe would try to raise equity, no sensible investor would put in equity above the conversion price.
Well testing results, another delay and a more down beat tone in the statement.
RichTheNewbie really? Chaarat have the opportunity for operational synergies with Lydian, I say they are soon out of the Shanta speculation.
Chaarat bid for Shanta looks unlikely now
My point is that they have only reached 6 mmscf/d based on hourly figures, not as great as producing above 6 mmscf for the whole day.
Interesting way of looking at reaching target. Meeting them on an "hourly basis". Feels like they had to put in that first in the rns before telling about the delays.
How much of the well cost should EOG recover due to this new tax / investment regim for oil and gas?
Based on this calculation
https://twitter.com/Stockpicking101/status/1577937843695001601
12 Sep the company comes out with ad-hoc production update, after strong August production and upbeat outlook. Then today Q3 total production is at the bottom of the guidance, due to problem with crusher in September. A problem the company most likely was aware of when they wrote the 12 Sep RNS. There is real no trust left.
He said debt free by Q3 2023. And yes I assume that includes a successful side-track. Cash flow at max 7 mmscf isnt that impressive with 5.3 mmscf hedged.
What would a good flow rate from JSR-01 be?
The well was drilled after period end. So cash probably lower now.
Faron Pharmaceuticals: Top-line Dose Variation Data From MATINS
2022-09-20
11:00
Faron has announced top-line data on dose variation from the phase I/II MATINS study with lead candidate Bexmarilimab. Redeye is encouraged by the results and looks forward to the further clinical development of the candidate.
Kevin Sule
Earlier this morning, Faron announced top-line data on bexmarilimab dose variation in MATINS patients. The MATINS trial is a phase I/LL study investigating the safety and efficacy of Bexmarilimab monotherapy in ten different hard-to-treat metastatic or inoperable solid tumor cohorts. In the initial part I (safety/dose-finding) and part II (dose confirmation), Bexmarilimab showcased a good safety profile and clinically relevant effect on overall survival (updated analysis show 14.9 months for patients who benefited from treatment compared to 4.4 months for those who did not). The latest segment of the trial, part III (dose exploration), focused on exploring higher dose levels and frequencies to determine the finalized dose for further studies with Bexmarilimab.
Data from the study showed that higher doses, up to 30mg/kg (previously 0.1-10 mg/kg), were well tolerated as was more frequent dosing of 1-3 mg/kg administered every week to every other week. This data suggests that bexmarilimab dosing can be effective across several dosing regimens, not being constrained by dose-limiting toxicity. We believe that this further indicates that combination therapy with anti-PD-1 treatment would also be well tolerated, boding well for the BEXMAB, BEXLUNG, and BEXCOMBO studies. following a detailed evaluation of this latest data, Faron expects to submit a full data package to the FDA to obtain regulatory advice for further clinical development of Bexmarilimab as a monotherapy last-line treatment and as an early-line combination therapy.
As also suggested in previous results, treatment with Bexmarilimab induced significant systemic interferon-gamma (IFN-?) increase – where the lower the pre-existing IFN-gamma response is, the higher the IFN-gamma levels will increase with Bexmarilimab treatment. This finding is truly essential in identifying and determining patients likely to benefit from treatment, which can be possible through a validated staining antibody. We argue that Faron is now well-positioned to drive a biomarker strategy to guide patient selection ahead successfully.
Overall, we are encouraged by the results from the dose exploration part of MATINS as it bolsters our view of Bexmarilimab’s safety profile and clinical relevance. While we view these data as positive, they align with our previous valuation assumptions. Accordingly, we do not make any adjustments to our valuation as of now.
We reiterate our fair value Base Case valuation of EUR 4 per share (Bull 10, Bear 2).
Another underwhelming datapoint. Where is the ramp-up Angus promised in the Friday RNS?
203k is past production not previous 2P.
Net 2P reserves at 30 Jun 2022. 0.27m, dosent make me jump up and down
Equivalent to 3.26 mmscf